Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $64,264.20 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,145 shares of the stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $29.96, for a total value of $64,264.20. Following the transaction, the insider now directly owns 52,011 shares in the company, valued at approximately $1,558,249.56. The trade was a 3.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Nur Nicholson also recently made the following trade(s):

• On Wednesday, January 22nd, Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total transaction of $120,137.64.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $30.76 on Friday. The firm has a fifty day moving average price of $31.95 and a 200 day moving average price of $33.25. The stock has a market cap of $3.83 billion, a PE ratio of -15.15 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the prior year, the business earned ($1.17) EPS. The company’s quarterly revenue was up 78.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D grew its position in Apellis Pharmaceuticals by 6.6% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after purchasing an additional 2,820 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Apellis Pharmaceuticals by 42.2% during the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after buying an additional 39,931 shares during the last quarter. Amalgamated Bank increased its position in Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after acquiring an additional 359 shares during the period. Profund Advisors LLC raised its stake in Apellis Pharmaceuticals by 90.7% during the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after acquiring an additional 20,435 shares during the last quarter. Finally, HighVista Strategies LLC lifted its position in Apellis Pharmaceuticals by 4.1% during the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after acquiring an additional 300 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Needham & Company LLC dropped their price objective on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company dropped their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Piper Sandler reduced their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Mizuho lowered their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Finally, Oppenheimer reduced their price target on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).